This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII)) produced by two different manufacturers (Novo Nordisk and Avecia) in healthy male volunteers.

Inclusion Criteria:

• Body Mass Index (BMI) between 18.5 and 30 kg/m2
• Good general health based on assessment of medical history, physical examination, ECG (electrocardiogram), and clinical laboratory data at screening, as judged by the physician
• Non-smokers

Exclusion Criteria:

• Known history of thromboembolic event(s) or potential thromboembolic risk as judged by the physician
• Blood transfusion within 3 months of trial start
• Positive for hepatitis B or C infection
• Positive for Human Immunodeficiency Virus (HIV) infection
• Excessive consumption of a diet deviating from a normal diet as judged by the physician
• Blood or plasma donation within the last 3 months prior to trial start
• Subjects with any history of migraine